Breaking News

European Court Orders Russia to Pay €1.87 Billion for Yukos Seizure
Tweet TWEET

Bioline RX, Mizrahi, Partner, Protalix: Israeli Equity Preview

The following stocks may rise or fall in Israeli markets. Stock symbols are in parentheses after the company names and prices are from the close unless otherwise stated.

The TA-25 Index declined 1.8 percent to 1,272.62 in Tel Aviv.

Ampal-American Israel Corp. (AMPL IT): The flow of gas from Egypt may be delayed a few days, TheMarker business daily reported, citing an Israeli government evaluation. The holding company that imports the fuel earlier said it expected resumption by the end of February. Ampal-American dropped 2.9 percent to 7.066 shekels.

Bioline RX Ltd. (BLRX IT): The biopharmaceutical company said a trial to test the safety and effectiveness of BL-1040 in post heart-attack patients will start in the second half. Bioline declined 1.3 percent to 2.724 shekels.

Partner Communications Co. (PTNR IT): The country’s second- largest mobile phone company was raised to “market perform” from “underperform” at Meitav Investment House Ltd. Partner fell 1.7 percent to 66.87 shekels.

Protalix BioTherapeutics Inc. (PLX IT): The biotechnology company failed to win U.S. approval of a plant-based medicine it’s developing with Pfizer Inc. to treat Gaucher disease. Protalix gained 3.4 percent to 36.20 shekels.

Space Communication Ltd. (SCC IT): The supplier of satellite communications services said it plans to offer Series Yud-Aleph bonds under a shelf registration originally filed in February 2010. Space Communication slipped 0.2 percent to 69.86 shekels.

To contact the reporters on this story: Calev Ben-David in Jerusalem at cbendavid@bloomberg.net; Ronit Goodman in Tel Aviv at rgoodman9@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.